Introduction: Cannabis use increases the risk of developing psychosis, and subjects with psychosis are more likely to use cannabis. However, studies on the influence of cannabis on psychotic dimensions, response to treatment, and functional outcomes showed conflicting results. Such heterogeneity may be due the inclusion of patients who were already under treatment, and lack of specificity in evaluations. We investigated whether cannabis use yields distinct symptom profiles and functionality in a cohort of antipsychotic-naïve patients at first episode of psychosis (FEP). Methods: This research is part of a prospective cohort study performed in Sao Paulo, Brazil. The baseline assessment was completed by 175 individuals, and 99 of them were reassessed in a ten-week follow up. We investigated the relationship between cannabis exposure variables (acute use, lifetime use and age at first use) and outcomes: symptom dimensions and functioning. Results: Individuals who reported acute use of cannabis had higher excitement symptoms at baseline, higher excitement and positive response rates, but no significant differences at follow-up. Additionally, more days of cannabis use in the last month predicted worse functionality and clinical impression at baseline but not at follow-up. Discussion: The acute use of cannabis influenced the clinical presentation at our FEP baseline assessment, but did not to influence symptoms or functional outcomes at 10-week follow-up. Additionally, acute cannabis users had a better response for excitement and positive symptoms. Higher excitement symptoms at presentation of FEP should raise concerns of possible acute use of cannabis. Longer follow-up times may elucidate whether the effects on functionality would be more evident later in disease development.
Introduction
Cannabis is related to psychosis in three main ways: cannabis use increases the risk to develop psychosis; is associated with earlier onset, especially among daily users and individuals who use high-potency cannabis (Di Forti et al., 2014) ; and subjects with psychosis are more prone to use cannabis (Archie et al., 2006) (Di Forti et al., 2009) (Libuy et al., 2018) . Additionally, subjects with higher genetic vulnerability to develop psychosis are especially sensitive to cannabis effects (Mustonen et al., 2018) (Caspi et al., 2015) . Despite the strong association between cannabis use and psychosis-related matters, there are some controversies about its relationship with psychotic symptoms. The hypothesis of a specific symptomatic psychosis caused by cannabis use (cannabis psychosis) has been refuted (Baldacchino et al., 2012) . However, recent studies showed that cannabis abuse is related to worse symptoms and functionality in psychotic patients, even though the physiological mechanisms and the quantitative aspects of this influence are still uncertain.
Most studies of cannabis influence on the clinical presentation of psychosis included chronic patients in the sample. This is an important limitation, because the effects of cannabis on disease onset were not evaluated, and several studies showed that early interventions are important to improve the chances of a better prognosis (DeRosse et al., 2010) (Moustafa et al., 2017) . Additionally, studies with cannabis designed specifically for FEP patients are biased by the inclusion patients who were already using antipsychotic drugs (Seddon et al., 2015 ) (González-Ortega et al., 2015 ) (González-Blanch et al., 2015 .
A better profile of cannabis effects on FEP individuals could help define tailored interventions and more accurate prognostic predictions. Even after the refutation of a specific cannabis psychosis, the underhttps://doi.org/10.1016/j.scog.2018.10.002 Received 16 July 2018; Received in revised form 29 October 2018; Accepted 31 October 2018 standing of the disease course -in terms of quantification and prediction of injury rate -in those patients would affect clinical practice (Baldacchino et al., 2012) .
To address these gaps in previous studies, we investigated whether cannabis use yields distinct symptoms and functionality in antipsychotic naïve FEP patients, using a ten-week follow up of a Brazilian cohort. We also analyzed the response to treatment for every symptom dimension, and functional outcomes of the FEP individuals who used cannabis. Our initial hypothesis was that patients who use cannabis will present more positive symptoms and worse functional outcomes at baseline and follow-up (Seddon et al., 2015) .
Methods

Study design
The present research is part of a prospective cohort study performed in Sao Paulo, Brazil, which examines sociodemographic, functional, and immune-inflammatory profiles, and symptomatic characteristics of antipsychotic naïve FEP individuals. Patients were followed during a course of treatment with risperidone to delineate the effects of this antipsychotic. We are still following and screening patients for longer follow-ups (6-month, 1 year and 2 years). All participants provided written informed consent prior to enrollment in this study. The study was approved by the Research Ethics Committee of UNIFESP (Sao Paulo, Brazil) and carried out in accordance with the Declaration of Helsinki.
Participants
This study analyzed a cohort of antipsychotic naive individuals at their First Episode of Psychosis (diagnosed by DSM-IV and SCID-I criteria) (American Psychiatric Association, 2000) (First et al., 1997) . The assessments used for this study were performed by trained psychiatrists at an emergency service in São Paulo, Brazil, between 2011 and 2018. The baseline assessment was performed at admission, and comprised 175 individuals who fulfilled the inclusion criteria of FEP, without previous use of antipsychotics. The follow up was performed ten weeks after treatment initiation and comprised 99 individuals. Exclusion criteria were: incomplete PANSS Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) assessment; evidence of any organic brain disease, substance-induced psychosis or history of head trauma with loss of consciousness.
Predictors and outcomes
Cannabis exposure variables
All cannabis exposure variables were assessed only at baseline. We measured the cannabis exposure using the Addiction Severity Index (ASI-6, Portuguese validated version) (Denis et al., 2013) (Cacciola et al., 2011) (Sartes, 2010) and some additional questions to better describe the cannabis consumption habits of the individuals. After the acquisition of cannabis use parameters, the following variables were defined: 1) Cannabis use in the last 30 days (acute use and number of days of use); 2) Age at first use of cannabis; 3) Cannabis lifetime use, categorized in a) Cannabis use (yes or no) and b) Heavy use (< 50 or ≥ 50 times during life).
Outcome variables
Two main outcomes were targeted: 1) Symptom dimensionsObtained by PANSS five-factor model (positive, negative, disorganized, excitement and depression/anxiety) (Higuchi et al., 2014) ; 2) Functioning -Measured by the Global Assessment of Functioning (GAF) (American Psychiatric Association, 2000) and Clinical Global Impression (CGI) (Lima et al., 2007) . Our secondary outcomes were: 1) PANSS total score; 2) response to treatment (reduction of > 50% in the total PANSS score from baseline to endpoint, after subtracting the minimum total PANSS score equal to 30 (Leucht et al., 2009 ); 3) Symptom Remission based on Andreasen et al. criteria (Andreasen et al., 2005) ; 4) Response rate in each specific symptom dimensions.
Possible bias and confounders
We considered duration of untreated psychosis (DUP), sex, and age as confounders. DUP was computed as the time elapsed, in days, between FEP and treatment initiation. We performed Bonferroni correction for all multiple comparisons. Furthermore, we treated the number of days of cannabis use as a possible confounder in the statistical analysis of acute use.
Our follow-up evaluation included 56.57% of the individuals assessed at baseline. To ensure that baseline and follow-up lengths were comparable, we performed a Mann-Whitney test for baseline outcomes comparing those who successfully completed the follow-up to those who dropped out of the cohort. The variables were: age, sex, PANSS total score and DUP. None of the p-values were significant (> 0.05), indicating that the losses due to dropout might be random, and the assessment lengths were comparable.
Statistical analysis
All statistical analyses were performed using SPSS-20 and RRstudio 1.0.153. We applied linear regression to investigate the association between predictors (all the cannabis exposure variables) and outcomes, and Mann-Whitney's test to study the effect of the categorical cannabis exposure variables on the mean outcomes. All the regressions were controlled for the confounders previously described, and for the mean comparison tests we evaluated Cohen's d effect size. Additionally, a Kruskal-Wallis test was used to compare all outcome variables between three groups: 1) Those who reported acute cannabis use; 2) those who reported past, but not acute, cannabis use, and 3) those who did not report cannabis use. Table 1 presents the descriptive analysis of the assessments at baseline (N = 175) and follow up (N = 99). At baseline, the mean age was 25.42 (SD = 7.12), and 65% of the subjects were male. Cannabis use was reported by 41.2% of the individuals: 26.3% reported heavy use (> 50 times in life), and 17.1% acute use ( Table 2 ). The follow up mean age was 25.1 (SD = 7.02), and 60% of the subjects were male. After the drop out losses at follow-up, cannabis use was reported by 39.4% of the individuals, while 23.2% reported heavy use (> 50 times in life), and 15.2% reported acute use. These results are similar to the prevalence findings reported in the literature (Myles et al., 2015) . Coutinho et al. Schizophrenia Research: Cognition 16 (2019) 12-16 
Results
Descriptive analysis
Results on symptoms
PANSS total score and DUP were not predicted by any of the cannabis exposure variables at either assessment. However, we found significant differences in specific symptom dimensions. Cannabis acute use affected the excitement dimension mean (W = 1592.5, P = 0.021, Cohen's d = 0.340). This difference was also observed in those who reported acute use when we performed a three-group comparison between previous lifetime users who were not acute users, acute users and non-users (Kruskal-Wallis chi-squared = 5.352, df = 2, P = 0.048). Before the corrections for the possible confounders previously described, the excitement dimension was significantly related to cannabis acute use and days of use in the last month. After the corrections, the results obtained for days of use (β = 0.210, P = 0.094, R 2 = 0.164) and acute use (β = 4.304, P = 0.051, R 2 = 0.061) showed a trend towards significance. At follow up, no significant association was found between cannabis exposure variables and symptom dimensions or functional outcomes. However, every PANSS symptom dimension mean scores were lower for the FEP individuals who reported acute use at baseline (Fig. 1) . We analyzed the response rate difference (Δ) between baseline and follow up PANSS -to verify if cannabis exposure also predicted the response profile. The acute use of cannabis modified the response rate of the positive (W = 342.5, P = 0.003, Cohen's d = 0.913) and excitement (W = 398, P = 0.005, Cohen's d = 0.781) dimensions. Both comparisons had large effect sizes. Additionally, in the three-group comparison of the means, the acute use group had higher response rate for the excitement (Kruskal-Wallis chi-squared = 7.740, df = 2, P = 0.021) and positive (Kruskal-Wallis chi-squared = 8.843, df = 2, P = 0.012) dimensions.
Functionality results
At baseline, a higher number of days of cannabis use in the last month predicted greater severity in Clinical Global Impression (β = 0.032, P = 0.006, R 2 = 0.181) and Global Assessment Functioning (β = −0.349, P = 0.032, R 2 = 0.093). Additionally, a younger age at first cannabis use predicted worse Clinical Global Impression (β = −0.070, P = 0.040, R 2 = 0.117). At follow up, we did not find any significant associations, except that the number of days of use in the last month predicted higher Δ for Clinical Global Impression (P = 0.026, R 2 = 0.127). The association between acute use of cannabis and the Δ for Global Assessment Functioning was not significant (P = 0.089, R 2 = 0.074).
Discussion
We found that cannabis use -especially acute cannabis use reported at baseline -influences symptoms and functionality in antipsychotic naïve FEP patients at the disease onset. Additionally, the acute use group of patients had distinct response rates in the positive and excitement symptom dimensions on a short-follow up. Our findings partially support our initial hypothesis: we could not find evidence of association between cannabis use and worse positive symptoms, but we found a significant one between acute cannabis use and worse excitement symptoms and functionality at baseline. Additionally, worse functionality was associated with younger age at first cannabis use. The finding of poorer functional clinical presentation is in line with several functional investigations of cannabis associations with FEP individuals (González-Blanch et al., 2015) (Bergh et al., 2016) .
At follow-up, all symptom dimension means were lower for those who reported acute use at baseline. Although none of these results were significant, patients who reported acute use at baseline showed higher functional, excitement and positive response rates. This result implies three possible conclusions: a better prognosis for this group of patients, which is not in line with previous literature (Seddon et al., 2015) (DeRosse et al., 2010); patients stopped using cannabis during the 10 week treatment, leading to significant remission; or there is a specific short-term improvement for these patients that does not lead to better future symptomatic presentations.
Previous studies of cannabis and psychosis had some limitations that could bias their findings. Including patients who already used antipsychotic drugs is an important source of bias if there is a better psychotic response profile for acute cannabis users during treatment. Additionally, the evaluation of the five specific PANSS symptom dimensions was essential to determine the worse presentation (excitement) and the better response rate (positive and excitement) of acute users. The absence of these specific symptomatic assessments could bias the results of previous studies. These limitations could help understand the conflicting results found in previous studies.
Our main result is that acute cannabis use influences functional and symptomatic outcomes before the FEP individuals start the antipsychotic treatment. Despite the fact that we did not measure cannabis variables at the 10-week follow up, all patients who reported use at treatment initiation were encouraged to stop the cannabis consumption. There is evidence of a high cannabis quit rate after initiating antipsychotic treatments (Mustonen et al., 2018) (Myles et al., 2015) . Taking this into account, a possible interpretation of our findings is that only acute cannabis use yields poorer prognosis of positive and excitement symptoms in FEP individuals. The response rates of these symptom dimensions were significant and had a large effects sizes, even though we did not find significantly worse positive symptoms at baseline.
A large cohort of FEP patients, enrolled for 12 months, showed significant association of cannabis consumption with worse functionality and symptoms (González-Blanch et al., 2015) . They used similar scales to assess the psychopathology, but they did not work with the PANSS dimensions. Their results showed that in all assessments, cannabis users -especially acute users -had lower functionality and higher positive and total PANSS scores. At the 12-month follow-up, the negative PANSS subscale scores were also increased. Our findings were not in line with the prospective findings of these studies. However, the association of acute cannabis use with worse symptoms and functional presentation are similar to our findings. Other studies showed association of cannabis consumption with other PANSS symptom subscales (González-Ortega et al., 2015) (Seddon et al., 2015 ) (Schnakenberg Martin et al., 2016 . However, these conflicting results may be caused by non-specific symptomatic evaluation. Some limitations should be considered while interpreting our results: 1) we did not use any objective method to quantify cannabis previous or acute use, i.e. urine, hair or blood sampling. Instead, we used several questions to better assess cannabis exposure; 2) Compared to other studies, we investigated a short follow-up period. However, the short follow-up may help in better understanding the timing of cannabis effects on the disease; 3) The follow-up in an outpatient facility specialized in FEP may promote better outcomes compared to standard treatments. Additional studies using different sampling approaches could clarify this point.
Our study supports the idea that acute cannabis use can impair symptoms and functionality in FEP individuals (Archie et al., 2006) (Seddon et al., 2015) (Mané et al., 2015) (DeRosse et al., 2010) . Our findings showed that excitement symptoms are higher for FEP acute cannabis users, and after treatment initiation, these patients had a higher specific symptom response rate for excitement and positive symptoms. It is important to verify whether these response and presentation profiles will be maintained at the next follow up assessments of our cohort.
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